TYRA

Tyra Biosciences Inc

TYRA, USA

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

https://tyra.bio

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TYRA
stock
TYRA

Assessing Tyra Biosciences (TYRA) Valuation Following Key Executive Hires to Support Advancing Clinical Pipeline simplywall.st

Read more →
TYRA
stock
TYRA

Stock Report: Why TYRA stock remains a top recommendation - July 2025 Rallies & Stock Portfolio Risk Management moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$32

Analyst Picks

Strong Buy

6

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.81

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-10.65 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-9.89 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.08

Low 1

High 0.3

Investors

* Institutions hold a combined 102.48% of the total shares of Tyra Biosciences Inc

1.

RA Capital Management, LLC

(22.888%)

since

2025/06/30

2.

Alta Partners Management Company, L.P.

(7.6558%)

since

2025/06/30

3.

Nextech Invest, Ltd.

(7.6099%)

since

2025/06/30

4.

Bvf Inc

(7.4004%)

since

2025/06/30

5.

Canaan Partners XI LLC

(6.7698%)

since

2025/06/30

6.

COMMODORE CAPITAL LP

(5.8164%)

since

2025/06/30

7.

TCG Crossover Management, LLC

(5.4376%)

since

2025/06/30

8.

HHG PLC

(5.3592%)

since

2025/06/30

9.

Vestal Point Capital LP

(4.9815%)

since

2025/06/30

10.

Kynam Capital Management, LP

(4.3717%)

since

2025/06/30

11.

BlackRock Inc

(3.5524%)

since

2025/06/30

12.

Vanguard Group Inc

(2.63%)

since

2025/06/30

13.

Farallon Capital Management, L.L.C.

(2.1461%)

since

2025/06/30

14.

5AM Venture Management, LLC

(1.7624%)

since

2025/06/30

15.

Sio Capital Management, LLC

(1.5203%)

since

2025/06/30

16.

Orbimed Advisors, LLC

(1.5097%)

since

2025/06/30

17.

Vanguard Total Stock Mkt Idx Inv

(1.4908%)

since

2025/07/31

18.

iShares Russell 2000 ETF

(1.1091%)

since

2025/08/31

19.

Balyasny Asset Management LLC

(1.0946%)

since

2025/06/30

20.

Biotech Growth Ord

(1.0885%)

since

2025/05/31

21.

Geode Capital Management, LLC

(1.0641%)

since

2025/06/30

22.

Marshall Wace Asset Management Ltd

(0.8032%)

since

2025/06/30

23.

State Street Corp

(0.7861%)

since

2025/06/30

24.

Fidelity Small Cap Index

(0.4528%)

since

2025/06/30

25.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4512%)

since

2025/07/31

26.

iShares Russell 2000 Value ETF

(0.392%)

since

2025/08/31

27.

iShares Biotechnology ETF

(0.3568%)

since

2025/08/31

28.

UTM IM GBP AXA Framlington Biotech

(0.231%)

since

2025/07/31

29.

Vanguard Russell 2000 ETF

(0.2164%)

since

2025/07/31

30.

Fidelity Extended Market Index

(0.2124%)

since

2025/07/31

31.

Victory Science & Technology

(0.2017%)

since

2025/06/30

32.

Multi-Manager Small Cap Eq Strat Inst

(0.1961%)

since

2025/07/31

33.

Schwab US Small-Cap ETF™

(0.1942%)

since

2025/08/30

34.

State St Russell Sm Cap® Indx SL Cl I

(0.1396%)

since

2025/08/31

35.

Schwab Small Cap Index

(0.1136%)

since

2025/07/31

36.

NT R2000 Index Fund - NL

(0.1093%)

since

2025/06/30

37.

iShares Micro-Cap ETF

(0.102%)

since

2025/08/31

38.

Vanguard Health Care ETF

(0.0885%)

since

2025/07/31

39.

NT R2000 Index Fund - DC - NL - 3

(0.0872%)

since

2025/06/30

40.

Extended Equity Market Fund K

(0.0836%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.5

EPS Estimate

-0.5014

EPS Difference

0.0014

Surprise Percent

0.2792%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.